Castle Creek Biosciences develops novel gene therapies to improve lives. The company focuses on cell and gene therapy for patients and families.

Castle Creek Biosciences

HealthTech provides management consulting services focused on community hospital management, including interim executive staffing, hospital management, technology, supply chain and consulting. The services are aimed at improving performance and sustainability in healthcare.

HealthTech

Castle Creek Biosciences is a late-stage company developing re-dosable gene therapies. It is preparing to launch a pivotal clinical trial of its lead candidate, 
D-Fi, for patients with dystrophic epidermolysis bullosa (DEB).

Horizon Technology Finance

U.S. Food and Drug Administration

Fidelity Management and Research Company

Valor Equity Partners

Paragon Biosciences

Castle Creek Biosciences, Inc.

The earliest description of what is now known as epidermolysis bullosa (EB) was by Austrian dermatologist Ferdinand Ritter von Hebra in 1870. It’s been 154 years and still there are very limited treatment options and no cures for EB. 

One out of every 20,000 U.S. births, or approximately 200 children yearly, are born with EB. This painful disorder requires a lifetime of daily wound care along with a variety of medical specialists. Those with severe forms of EB usually do not survive past 35 years of age. 

At Castle Creek, we hope our work can one day deliver relief to the people living with EB and their families.

What an incredible four days our team had at the debra of America Care Conference in Atlanta! 

We appreciate everyone who connected with us to share their stories about how epidermolysis bullosa (EB) has impacted their lives. 

Special shout out to our CEO Matthew Gantz for his presentation on our upcoming phase 3 clinical trial. 

#dcc2024 #debracareconference #epidermolysisbullosa

Our CEO, Matthew Gantz, is heading to Atlanta for the debra of America Care Conference, an annual event where people living with epidermolysis bullosa and their families gather for knowledge sharing in a nurturing and supportive environment. 

On July 30, Matt will be sharing an update on Castle Creek’s preparations for a phase 3 clinical trial for a potential treatment for dystrophic epidermolysis bullosa (DEB).  Hope to see you there!

https://lnkd.in/ghMU3QnQ

We’re proud to be a Platinum Sponsor of the upcoming debra of America Care Conference! Our work is fueled by people living with epidermolysis bullosa, who experience a lifetime of challenges that no one should ever have to go through.

Recently, Castle Creek hosted Michelle and Marley, two people living with Epidermolysis Bullosa (EB). 

Michelle shared her story of growing up with EB and how she navigates her day as an adult living with EB.  

Nine-year-old Marley and his mother, Shauna, have just begun their journey into advocacy activities. The room was filled with the warmth of Marley’s smile and his big personality connected with the crowd while Shauna talked to the CCB team. 

These first-hand stories of Michelle and Marley really hit home. Their stories, among the thousands of others, are what fuel our work at Castle Creek. 

We know that a person with EB has to overcome numerous challenges every single day. Simple tasks like bathing and eating can take hours, and that’s just the beginning. 

While there is no cure for EB, we are hopeful that our work can one day help provide relief for those living with this painful condition. 

Learn more about Michelle’s life with EB here: https://lnkd.in/gjFFdYHY

On National Doctors' Day, we celebrate the invaluable contributions doctors  make to healthcare and the critical role they play in healing and saving lives.

Today, we remember the impact of Dr. Martin Luther King, Jr. who called for unity and understanding, to create a world where everyone has the opportunity to flourish. #martinlutherkingjr

Metric
Company Name	Castle Creek Biosciences	HealthTech
Symbol
MSH ID	COM:CASTLECREEKBIO	US:HEALTH-TECH
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Healthcare Consulting
Country	US	US
Stage
Employee Count
Website	castlecreekbio.com	health-tech.us
LinkedIn	castlecreekbio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CAST

COM:CASTLECREEKBIO

Castle Creek Biosciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue